Advertisement

Topics

Takeda Pharma: VISIBLE 1 Study Of Vedolizumab Meets Primary Endpoint

04:24 EDT 19 Jul 2018 | RTTNews

Japan's Takeda Pharmaceutical Co. Ltd. (TKPYY.PK) announced Thursday that new phase 3 data show investigational subcutaneous or SC formulation of Vedolizumab meets primary endpoint in achieving clinical remission at week 52 in patients with moderately to severely active ulcerative colitis.

Original Article: Takeda Pharma: VISIBLE 1 Study Of Vedolizumab Meets Primary Endpoint

NEXT ARTICLE

More From BioPortfolio on "Takeda Pharma: VISIBLE 1 Study Of Vedolizumab Meets Primary Endpoint"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...